Frailty indices aid individualized stroke prevention in elderly with cardiovascular disease, emphasizing multidisciplinary care, antithrombotic strategies, and considering sex- and age-related treatment factors.

The 2026 guidelines replace the 2018 guidelines, offering updated recommendations for managing dyslipidemia, focusing on evaluation, management, and monitoring of lipid disorders.

Review highlights that abnormal BMI—especially obesity—negatively affects oocyte quality through lipotoxicity, mitochondrial dysfunction, oxidative stress, DNA damage, and epigenetic alterations, leading to poorer fertility outcomes and increased miscarriage risk.

Pilot randomized placebo-controlled study suggests a combined Lactiplantibacillus plantarum ECGC 13110402 and plant sterol/stanol supplement may improve lipid profiles, increase vitamin D levels, and favorably modulate gut microbiota in adults with coeliac disease and hypercholesterolemia.

Case highlights pregnancy-associated severe hypertriglyceridemia in a woman with diabetes and hypothyroidism, complicated by acute pancreatitis, successfully managed using plasmapheresis, insulin infusion, fenofibrate, and coordinated multidisciplinary obstetric care.

This case demonstrates successful treatment of rare Candida auris ventriculitis associated with an external ventricular shunt using susceptibility-guided combination antifungal therapy and definitive source control through shunt removal, highlighting importance of aggressive multidisciplinary management.

This case report shows evinacumab significantly improved lipid profiles and atherosclerosis-related markers in homozygous familial hypercholesterolemia, suggesting broader cardiovascular benefits beyond LDL-cholesterol reduction in refractory disease management.

Aggressive LDL-C reduction is central to secondary ASCVD prevention. Statins, with ezetimibe or PCSK9 inhibitors, lower risk significantly, supporting stricter guideline-recommended LDL-C targets across coronary, cerebrovascular, and peripheral artery disease.

Study shows triglyceride-glucose index predicts mortality differently by metabolic status—linear risk increase in normoglycemia, U-shaped association in diabetes, none in dysglycemia—highlighting TyG as a useful, context-dependent prognostic marker.

Dyslipidaemia, driven by elevated LDL-C and other lipids, increases ASCVD risk; management includes lifestyle changes, statins, and combination therapies, with emphasis on early diagnosis, risk modifiers, and achieving treatment targets.

Meta-analysis of RCTs shows melatonin in CKD modestly increases HDL, reduces oxidative stress, and improves sleep, with no significant effects on other lipids or inflammation; larger trials needed for confirmation.

Randomized trial shows combined Mentha spicata, Amaranthus, flavonoids, and B vitamins improve lipid profile, reducing LDL and total cholesterol while increasing HDL, especially at higher doses, in borderline dyslipidemia patients.

Review positions incretin polyagonists (e.g., tirzepatide) as potent non-surgical obesity alternatives to bariatric surgery, achieving comparable weight loss, glycemic control, and cardiometabolic benefits via multi-receptor gut hormone effects.

Case highlights falsely low triglyceride readings in hypertriglyceridemia-induced pancreatitis due to analyzer alarm failure; improved lab protocols, including lipemic index checks and enhanced alerts, are essential for accurate diagnosis.

Review highlights major implementation gap in lipoprotein(a) testing despite strong cardiovascular risk evidence. It discusses causal associations, evolving screening guidelines, and emerging RNA-targeted therapies achieving substantial Lp(a) reduction, advancing precision cardiovascular medicine.

Case report shows supervised intensive lifestyle intervention with high-protein caloric restriction and progressive aerobic-resistance training led to 50-kg weight loss, improved fitness and blood pressure in severe CAD patient without ischemic complications.

Review highlights brimonidine, a selective α2-agonist, for dermatologic use. It reduces rosacea-related erythema via vasoconstriction and anti-inflammatory effects, with minimal systemic absorption. Novel nanocarriers and analogues enhance delivery, efficacy, and therapeutic versatility.

Review highlights curcumin’s multi-organ metabolic benefits despite low bioavailability, driven by intestinal accumulation, microbiota modulation, antioxidant (Nrf2), mitochondrial (AMPK/PGC-1α), and anti-inflammatory (NF-κB) pathways, improving insulin resistance, dyslipidemia, and metabolic disease outcomes.